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Introduction. Microbial pathogens, one of them is Helicobacter pylori (H. pylori), have frequently been implicated in the
atherogenesis. Endothelium-derived nitric oxide (NO) is synthesized from L-arginine by nitric oxide synthase (NOS) and plays
a pivotal role in the regulation of vascular tone. Asymmetric dimethylarginine (ADMA) is the most potent endogenous NOS
inhibitor. Elevated levels of ADMA have been reported in many circumstances associated with a high cardiovascular risk. The aim
of the present study was to investigate whether the eradication of H. pylori infection aﬀects serum ADMA levels. Materials and
Methods.F o r t y - t w oH. pylori-positive patients were enrolled in the study. Triple therapy for 14 days were given to all patients.
Serum ADMA levels were measured at baseline and 2 months after therapy. Results. Eradication was achieved in 34 (81%) patients.
The mean serum ADMA levels before and after therapy were 1,77 ± 0,30 and 1,67 ± 0,29ng/mL in the group with H. pylori
eradicated and 1,63±0,28 and1,56±0,32ng/mLinthenoneradicated, respectively. Wedetected statisticallysigniﬁcantdecreased
serum ADMA levels after therapy in H. pylori eradicated group. Conclusion. These ﬁndings have indicated that eradication of H.
pylori infection may decrease the risk of atherosclerosis and cardiovascular events.
1.Introduction
Immunoinﬂammatory events due to chronic infection are
thought to be one of the deﬁnitive atherogenetic processes
[1]. Evidences in favor of this hypothesis are derived from
in-vitro experimental and seroepidemiologic studies [2, 3].
Helicobacter pylori (H. pylori) is the most frequently
encountered bacterial infection worldwide [4]. It is localized
within the gastric mucosa leading to life-long inﬂammation
[4,5].H.pylorihasbeenaccusedinthepathogenesisofmany
diseases, either digestive or nondigestive type. One of the
most controversial nongastric diseases for that H. pylori held
responsible is coronary heart disease [6–10].
Nitric oxide (NO) is synthesized from L-arginine by
nitric oxide synthase (NOS) [11] and is a substance that
plays an important role in vascular homeostasis regulating
vessel tonus [12]. At the same time, it counteracts some
vital steps in atherosclerosis such as platelet aggregation,
leukocyte-endothelium interaction, and proliferation of vas-
cular smooth muscle cells [12, 13]. The evidences derived
from in vivo and in vitro studies give rise to think NO
is a decisive regulatory molecule in atherogenesis and
arteriogenesis that are major processes for the formation of
collateral arteries [14–17].
Asymmetric dimethylarginine (ADMA) is an endoge-
nous competitive inhibitor of endothelial NOS and decreases
its production and bioavailability [18]. ADMA is produced
by methylation of arginine remnants during normal protein
cycle in many tissues including vascular endothelium [12].
It is metabolized to citrulline via dimethylaminohydrolase
[12, 19].2 Mediators of Inﬂammation
A lot of data have recently been published on the
importance of ADMA in endothelial dysfunction as a
cardiovascular risk factor [20–23].
Intheliterature,thereareaveryfewnumberofstudieson
serum ADMA levels in H. pylori infections and those studies
reveal somehow controversial results [11, 20]. The eﬀects of
H. pylori eradication on serum ADMA levels have not been
evaluated recently. In the present study, we were interested
to see the eﬀects of H. pylori eradication on serum ADMA
levels.
2. Methods
2.1. Patients. Forty-two patients with dyspeptic symptoms
were enrolled into the study. Exclusion criteria were prior
eradication therapy for H. pylori, antiulcer drug use within
last 1 month, gastrointestinal system and other organ
malignancies, inﬂammatory and infectious diseases, and
prior gastric surgery. Patients with chronic diseases such as
ischemic heart disease, diabetes mellitus, or hypertension
were not included in the study. The state of H. Pylori
infection was diagnosed by 14C-urea breath test.
Eradication therapies consisted of lansoprazole 30mg
(2 × 1/day), clarithromycin 500mg (2 × 1/day), and amoxi-
cillin 1000mg (2 × 1/day) taken for 2 weeks and used in all
participants.
In all the patients, eradication was veriﬁed by means of
14C-urea breath test 2 months after H. Pylori eradication
treatment.
This study was conducted with the permission of the
local ethics committee of Zonguldak Karaelmas University
Faculty of Medicine, Zonguldak, Turkey.
Fasting blood samples of the subjects were drawn for the
analysisbeforeand2monthsafterH.Pylorieradicationtreat-
ment. The blood samples were kept at room temperature
for 30min, and then sera were separated from the cells by
centrifugation at 3000rpm for 5min. Serum samples were
stored at −80◦C until the day of analysis.
2.2. Measurement of ADMA Levels. Serum ADMA levels
were measured by a commercially available kit (Immun
Diagnostik AG, Bensheim, Germany) based on enzyme-
linked immunosorbent assay (ELISA) method.
2.3. Statistical Analysis. Statistical analyses were performed
usingthestatisticalpackageforthesocialsciences(SPSS,Ver-
sion 13.0). Results were expressed as the means ± standard
deviations. In the comparison between groups, statistically
signiﬁcant diﬀerences were assessed by the Wilcoxon signed
rankstestorpairedt tests.P<. 05wasconsideredstatistically
signiﬁcant.
3. Results
Forty-two patients with dyspeptic symptoms (20 males, 22
females) with mean age of 39,1 ± 10,6 years (min 19, max
54) were enrolled into the study.
Table 1: Pretreatment and posttreatment ADMA levels.
ADMA
pretreatment
(ng/mL)
ADMA
posttreatment
(ng/mL)
P
H. pylori eradicated
group 1,77 ±0,30 1,67 ±0,29 <.05
H. pylori non-eradicated
group 1,63 ±0,28 1,56 ±0,32 NS
NS: Not signiﬁcant.
Eradication was achieved in 34 (81%) patients. The
mean serum ADMA levels before and after therapy were
1,77 ± 0,30 and 1,67 ± 0,29ng/mL in the group with H.
pylori eradicated and 1,63 ± 0,28 and 1,56 ± 0,32ng/mL in
the noneradicated, respectively. We could detect statistically
signiﬁcant decrease in serum ADMA levels after H. pylori
therapy in H. pylori eradicated group (P<. 05; Table 1).
4. Discussion
H. pylori is a known causal agent of several gastrointestinal
diseases and has also been implicated in ischemic heart
disease. However, the role of H. Pylori in the pathogenesis
of atherosclerosis is controversial and the mechanism in this
association is also unclear. Several diﬀerent mechanisms are
proposed for the role of H. pylori in ischemic heart disease
[1–4, 9, 10, 24].
In the present study, we investigated to see the eﬀects
of H. pylori eradication on serum ADMA levels, an NOS
inhibitor. The analysis showed that H. Pylori eradication
was associated with a signiﬁcant reduction in serum ADMA
levels. In the literature, these are the ﬁrst data that have
shown the eﬀects of H. pylori eradication therapy on serum
ADMA levels.
Nitric oxide is a substance derived from an aminoacid, L-
arginine, by an endothelial NOS enzyme and plays a crucial
role in maintaining vascular homeostasis by regulating vessel
tonus [12].
ADMA is a naturally occurring amino acid that has the
property of inhibiting the activity of NOS [25]. ADMA is
widely present throughout the body [11]. ADMA is the most
potent endogenous NOS inhibitor [25].
Currently available experimental and clinical evidence
suggests that even small modiﬁcations of circulating ADMA
levels signiﬁcantly change vascular NO production, vascular
tone, and systemic vascular resistance [26, 27].
ElevatedADMAlevelshavebeendetectedinalargenum-
ber of diseases associated with an impaired endothelial L-
arginine-NO pathway, such as atherosclerosis, hypercholes-
terolemia, chronic heart failure, type 2 diabetes mellitus,
stroke, hyperhomocysteinemia, and hypertension [25, 26,
28]. Moreover, ADMA has recently been shown to be a risk
factor for cardiovascular disease [29, 30].
H. pylori which is a spiral-shaped gram-negative
microorganism causes one of the most prevalent chronic
infections worldwide [4]. H. pylori typically leads to a
life-long chronic infection in the stomach after exposure.Mediators of Inﬂammation 3
H. pylori ﬁrst colonizes on the gastric epithelium within the
mucous layer. Then, it causes active chronic inﬂammation
which is composed of gastric submucosal neutrophilic and
monocytic inﬁltration. H. pylori plays a proinﬂammatory
role by inducing various gastric mucosal mediators regulat-
ing the motion of neutrophils and other leukocytes, which
leads to gastric mucosal damage and epithelial remodeling
[6, 31, 32].
The reason whyADMA increased inH. pylori is not clear.
TheproductionofendogenousADMAisinﬂuencedbymany
factors. Proinﬂammatory factors could induce oxidative
stress to increase ADMA level in cardiovascular tissues
via reduction of dimethylarginine dimethylaminohydrolase
(DDAH) activity that degrades ADMA [11, 33–36]. In
addition, TNF-alpha increased ADMA in endothelial cells
[37]. H. pylori infection was proven that oxidative stress [38–
40] and cytokine levels like TNF-alpha [40, 41]c h a n g e d
in chronic inﬂammation secondary to inﬂammatory cell
proliferation in gastric mucosa. Those changes of cytokine
levels and oxidative stress in H. pylori infection might cause
ADMA level elevations. Also H. pylori infection might itself
produce ADMA [20, 42]. Furthermore, chronic H. pylori
infection might decrease the absorption of micronutrients,
hence, causing an imbalance in homocysteine-methionine
system,soincreasingmethylreservoirandthenADMAlevels
[20, 43].
Very few studies have been found in the literature
stressing on ADMA levels in H. pylori infection. Marra et al.
found that ADMA levels increased in H. pylori-positive case
group compared to negative control [20]. They suggested
that eradication of H. pylori might decrease the risk of
cardiovascular disease by decreasing serum ADMA levels.
However, they did not investigate the eﬀect of H. pylori
eradication on the ADMA levels.
In another study conducted by Zhang et al., they found
ADMA at high levels in gastric juice of H. pylori-positive
cases whereas did not encounter any diﬀerence between H.
pylori-positive and negative patients with respect to plasma
A D M Al e v e l s[ 11].
In the present study diﬀerent from the previous ones
we focused that H. pylori eradication signiﬁcantly decreased
the serum ADMA levels. We have postulated that H. pylori
eradication might be important in preventing the diseases,
for example, cardiovascular diseases, related to ADMA by
decreasing its serum levels.
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